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Research Brief 
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Abstract 
Obesity is a well-known risk factor for colorectal cancer but precisely how it influences risks of 
malignancy remain unclear. During colon cancer development in humans or animals, 
attenuation of the colonic cell surface receptor guanylyl cyclase C (GUCY2C) that occurs due to 
loss of its paracrine hormone ligand guanylin contributes universally to malignant progression. 
In this study, we explored a link between obesity and GUCY2C silencing in colorectal cancer. 
Using genetically engineered mice on different diets, we found that diet-induced obesity caused 
a loss of guanylin expression in the colon with subsequent GUCY2C silencing, epithelial 
dysfunction and tumorigenesis. Mechanistic investigations revealed that obesity reversibly 
silenced guanylin expression through calorie-dependent induction of endoplasmic reticulum 
stress and the unfolded protein response in intestinal epithelial cells. In transgenic mice, 
enforcing specific expression of guanylin in intestinal epithelial cells restored GUCY2C signaling, 
eliminating intestinal tumors associated with a high calorie diet. Our findings show how caloric 
suppression of the guanylin-GUCY2C signaling axis links obesity to negation of a universal tumor 
suppressor pathway in colorectal cancer, suggesting an opportunity to prevent colorectal 
cancer in obese patients through hormone replacement with the FDA-approved oral GUCY2C 
ligand linaclotide. 
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Introduction 
The precise molecular mechanisms by which obesity influences neoplastic transformation, 
including colorectal cancer, continue to be one of the most perplexing and provocative 
questions in cancer research. In that context, how obesity influences canonical signaling 
pathways underlying tumorigenesis remains incompletely defined. Guanylyl cyclase C 
(GUCY2C), expressed selectively in intestinal epithelial cells, is the receptor for diarrheagenic 
bacterial heat-stable enterotoxins (STs) and the gut paracrine hormones, guanylin in colon and 
uroguanylin in small intestine (1). This paracrine axis comprises a tumor suppressing circuit 
whose dysregulation universally characterizes colorectal carcinogenesis across species (2, 3). 
Indeed, guanylin is one of the most commonly lost gene products in colorectal tumorigenesis 
and its loss is one of the earliest events in intestinal transformation (2, 4, 5). Loss of guanylin 
silences GUCY2C producing intestinal epithelial dysfunction disrupting homeostatic mechanisms 
organizing the crypt-villus axis including proliferation, DNA damage sensing and repair, and 
metabolic programming which contributes to tumorigenesis (6-8). Here, we demonstrate that 
diet-induced obesity suppresses guanylin expression and silences GUCY2C through calorie-
dependent ER stress, contributing to tumorigenesis. 
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Materials and Methods 
Animal models 
C57BL/6 mice were purchased from NCI, while Balb/c (Stock Number 000651) and ob/ob 
(B6.Cg-Lepob/J; Stock Number 000632) mice were purchased from JAX. Mice were acquired at 4 
wks of age, acclimated for 2 wks, and fed Lean diet (LabDiet 5010; 3.0 kcal/g, 12.7% from fat 
and 58.5% from carbohydrate), HF diet (TestDiet 58Y1; 5.1 kcal/g, 61.6% from fat and 20.3% 
from carbohydrate) or HC diet (TestDiet 58Y2; 3.8 kcal/g, 10.2% from fat and 71.8% from 
carbohydrate) as indicated (Supplemental Table 1). Preliminary studies revealed that 4-6 weeks 
of a high fat diet was required to induce guanylin suppression. Gucy2c-/- mice, generated by 
inserting a neomycin resistance gene into the first exon, were bred, maintained, genotyped, 
and functionally characterized as described (7). Sibling Gucy2c+/+ and Gucy2c-/- mice from five 
different Gucy2c+/- breeding pairs [(generation 16 by backcrossing to the C57BL/6J mice 
obtained from JAX (Stock Number 000664)] were used to generate mice for the experiments. 
ROSA-STOPflox-Guca2a mice were generated by standard procedures in the Thomas Jefferson 
University transgenic mouse facility as described (9). Expression of the GUCY2C ligand, guanylin 
(GUCA2A), is regulated by the ROSA26 promoter followed by a STOP codon flanked by two loxP 
sites upstream of full length Guca2a in ROSA-STOPflox-Guca2a mice (Fig. 4A). Removal of the 
STOP codon by Cre recombinase activates constitutive transcription of Guca2a driven by the 
ROSA26 promoter (Fig. 4A). The murine villin promoter targets stable and homogeneous 
expression of transgenes in small and large intestine along the crypt-villus axis, in differentiated 
enterocytes, as well as in the immature, undifferentiated cells of the crypt. Villin-Cre-ERT2 mice 
were obtained from S. Robine (Institut Curie, Paris, France). Villin-CreERT2 mice express Cre 
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recombinase in intestinal epithelial cells. Intraperitoneal injection of tamoxifen (20 mg/Kg BW) 
for 5 consecutive days activates CreERT2 to mediate genetic recombination. Villin-CreERT2 mice 
were crossed with ROSA-STOPflox-Guca2a mice to generate hemizygous ROSA-STOPflox-Guca2a-
vil-Cre-ERT2 mice. Villin-CreERT2 mice were paired with hemizygous ROSA-STOPflox-Guca2a-vil-
Cre-ERT2 mice to produce ROSA-STOPflox-Guca2a-vil-Cre-ERT2 mice and corresponding littermate 
controls lacking the ROSA-STOPflox-Guca2a transgene. Both Villin-CreERT2 and ROSA-STOPflox-
Guca2a mice were on the C57BL/6 background. Xbp1ΔIEC (Villin-Cre+-Xbp1fl/fl) mice were 
generated by breeding Xbp1fl/fl and Villin-Cre mice. Xbp1fl/fl mice were generated by targeting 
loxP sites to introns flanking exon 2 and backcrossed >8 generations onto C57BL6 mice (10). 
Xbp1fl/fl mice served as genotype controls (11). Mice were housed in light-cycled and climate-
controlled barrier animal facilities at Thomas Jefferson University (C57BL/6J, Balb/c, ob/ob, 
Gucy2c-/-, ROSA-STOPflox-Guca2a-vil-Cre-ERT2, ROSA-STOPflox-Guca2a) and Harvard Medical 
School (Xbp1ΔIEC, Xbp1fl/fl). All experiments were performed in compliance with the Thomas 
Jefferson University and Harvard University Animal Care and Use Guidelines and approved 
animal protocols. 
Genotyping 
Gucy2c genotype was confirmed by PCR with primers: forward: 5'-
AGGTCATGACGTCACTGCTGGGCC-3'; reverse: 5'-TGTCCAGTCCTTCCTCCACAG-3'; neomycin: 5'-
GGTGGGCTCTATGGCTTC-3' (7). ROSA-STOPflox-Guca2a genotype was confirmed by PCR with 
primers: forward: 5'-CCGCCGTTGTTGTTATTGTAG-3'; reverse: 5'-GTTGTGGTG ATAGGTGGCAAG-
3'. Villin-Cre-ERT2 genotype was confirmed by PCR with primers: forward: 5'-
GAAAATGCTTCTGTCCGTTTG-3'; reverse: 5'-ATTGCTGTCACTTGGTCGTG-3' (9). 
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Colorectal tumorigenesis model 
For Gucy2c+/+ (Lean, HF) and Gucy2c-/- (Lean) mice, azoxymethane (AOM 8 mg/kg; Sigma, St. 
Louis, MO) was administrated to mice (6 wks old) through intraperitoneal injections weekly for 
6 wks. Tumors were enumerated and their sizes were quantified 8 wks after the last AOM dose 
under a dissecting stereomicroscope by blinded analysis. Tumor burden per animal was 
calculated as the sum of the area (diameter2) of individual tumors (7). For the ROSA-STOPflox-
Guca2a-vil-Cre-ERT2 model and corresponding controls (Fig. 4c), mice were on HF diet starting 
at 4 wks of age. Tamoxifen (20 mg/kg IP) was administered every 4 wks to enforce guanylin 
expression starting at 4 wks until tumor enumeration. Six doses of AOM (10 mg/kg) weekly 
were administrated starting at 5 wks of age. Tumors were enumerated and their sizes 
quantified at 22 wks of age (6, 7). For the Gucy2c+/+ (Lean, HC) mice, AOM (12 mg/kg) was 
administrated to mice (6 wks old) weekly for 6 wks. Tumors were enumerated and their sizes 
quantified 12 wks after the last AOM dose. The doses of AOM in different diet models were 
established in pilot studies to ensure at least ~50% tumor incidence in experimental cohorts. 
Human tissues 
Human distal colonic mucosal specimens were obtained from patients undergoing surgery 
under a protocol approved by the Thomas Jefferson University Institutional Review Board 
(control no. 01.0823). 
Cell culture and lentivirus infection 
Caco2 C2BBE1 cells were obtained from ATCC (CRL-2101), maintained and extended in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Cellgro, Catalog No. 10-013), supplemented with 
0.01 mg/ml human transferrin, and 10% fetal bovine serum (FBS). HEK293T cells (ATCC, Catalog 
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No. ACS-4500) were maintained in DMEM with 10% fetal bovine serum. For PERK inhibitor 
experiments, C2BBE1 cells were incubated in DMEM supplemented with 0.01 mg/ml human 
transferrin without FBS. Cells were pre-treated with 10 g/ml PERK inhibitor I (GSK2606414, 
EMD Millipore, Catalog No. 506190) for 30 min before induction of ER stress by 2.5 g/ml 
tunicamycin (Sigma-Aldrich, Catalog No. T7765) for 24 h. For ER stress experiments, cells were 
treated with various concentration of tunicamycin, or 500 nM thapsigargin (Sigma-Aldrich, 
Catalog No. T9033), for 24 h and 48 h before analysis. For siRNA experiments, HEK293 cells 
were transfected with Stealth siRNA (Life Technologies) siPERK (HSS190343) or Negative 
Control siRNA (Catalog Number 12935-300) using Lipofectamine RNAimax Transfection Reagent 
(Life Technologies). The next day, cells were transfected with 0.5 g of a bi-directional CMV 
plasmid designed to co-express guanylin protein and a zsgreen fluorescence marker using 
FUGENE HD Transfection Reagent (Promega). After 3 h, cells were incubated in media 
containing 1 g/mL tunicamycin or DMSO (control) for 24 h and then analyzed. 
Tissue preparation 
Mucosal layers from mouse distal colons were frozen immediately in liquid nitrogen and stored 
at -80oC until protein or RNA analysis. For immunostaining, specimens were fixed overnight in 
4% formaldehyde at 4oC, dehydrated through a series of graded acetone and ethanol washes, 
and embedded in paraffin (6, 7). Paraffin sections (5 µm) were mounted (5 
sections/slide/mouse) for immunohistochemistry or immunofluorescence staining (7). 
RNA analysis 
Total RNA was isolated by RNeasy Mini Kit (Qiagen, Catalog No. 74104) as directed by the 
manufacturer's instructions. Two-step RT-PCR was performed using TaqMan® reverse 
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transcription reagents (Life Technologies, Catalog No. N8080234) and TaqMan® universal 
master mix (Life Technologies, Catalog No. 4440038) to perform quantitative RT-PCR using 
GUCA2A primer/probe for TaqMan® Gene Expression Assays (Mm00433863_m1, Hs 
00157859_m1) in an ABI 7000 Sequence Detection System (Applied Biosystems)(7, 12). Relative 
expression was calculated using the 2-∆∆CT method utilizing villin1 (Life Technologies, 
Mm00494146_m1, Hs00200229_m1) as the internal control (9). 
Immunostaining and immunofluorescence 
Ki-67 served as a marker of proliferation, and immunohistochemistry was performed as 
described (7). Tissue specimens were deparaffinized and rehydrated, followed by heat-induced 
epitope retrieval (10 mmol/L citrate buffer, pH 6.0). After quenching with 3% H2O2 in TBS-T 
(Tris-buffered saline with 0.5% Tween 20) and blocking with 5% milk in TBS-T, proliferative cells 
were detected by overnight incubation with anti-Ki67 antibody (Dako, Clone TEC-3, Code No. 
M7249), followed by biotin-labeled secondary antibody and Histostain IHC detection kit for 
visualization (Life technology). Ki-67-positive cells were quantified by blinded-analysis from 5 to 
15 crypt-villus units/segment/mouse. Crypt number was estimated from complete crypts per 
transverse cross-section in 5 sections per mouse. Results reflect means ± SEM of at least 5 
animals in each group. For guanylin detection, heat-induced antigen retrieval was done in 10 
mmol/L citrate buffer pH 8.5, blocked in 5% milk in TBS-T supplemented with 3% donkey serum 
for 1 h at RT and followed by overnight incubation with rabbit anti-guanylin antibody at 4oC (gift 
from Dr. Michael Goy, University of North Carolina, NC). Specimens were mounted in ProLong® 
Gold antifade reagent with DAPI after incubation with fluorescence labeled secondary antibody 
(Alexa Flour, Life Technologies) for visualization. Fluorescence was visualized using a Zeiss LSM 
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510 Meta Confocal Laser Scanning Microscope. Intestine specimens from Xbp1ΔIEC and control 
Xbp1fl/fl mice were obtained from Drs. F.M. Tomczak and R.S. Blumberg (11) and paraffin 
sections prepared as described. 
Immunoblot analyses 
Protein was extracted and homogenized in M-PER reagent (Thermo Fisher Scientific, Catalog 
No. 78501) supplemented with protease and phosphatase inhibitors (Roche Applied Science, 
No. 05892970001 and 04906837001), and then subjected to SDS-PAGE and immunoblotting 
using antibodies as follows: actin (Cell Signaling, 4967S), Bip (Cell Signaling, 3177S), -catenin 
(Cell Signaling, 8480S), CHOP (Cell Signaling, 2895S), cyclin D1 (Cell Signaling, 2978S), eIF2α (Cell 
Signaling, 9722S), GUCA2A (LSBio, LS-C3244, LS-C166741), hexokinase II (Cell Signaling, 2106S), 
Phospho-AKT (Cell Signaling, 9271S), Phospho-eIF2α (Cell Signaling, 3597S), -H2AX (Cell 
Signaling, 2577S), Phospho-VASP (Cell Signaling, 3114S), villlin-1 (Cell Signaling, 2369S). 
Secondary antibodies were from Santa Cruz Biotechnology. Staining intensity of specific bands 
quantified by densitometry (Kodak) was normalized to that for villin-1. Immunocomplexes were 
detected by SuperSignal West Dura Substrate (Thermo Fisher Scientific, No. 37071). Average 
relative intensity reflects the mean of 5~15 individual animals per cohort or ≥3 independent 
experiments with cells. 
Growth curves and food intake 
Five mice were housed together, each mouse was weighed weekly, and at least 20 mice from 
each cohort were followed. In the ob/ob restricted diet experiment, 3 mice were housed 
together and 6 mice from each cohort were weighed. For food intake, mice were separated into 
individual cages with wire-mesh floors, and given a pre-weighed amount of chow each day. All 
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mice were given ad libitum access to water for the duration of the experiment. Food 
consumption was measured daily for 7 d to establish average food intake. 
Statistical analyses 
Minimum cohort sizes were computed using a power of 80% and a significance level of 0.05 (1-
tailed test) employing a priori predictions of effect size and variance established by preliminary 
studies or literature review. Operators were blinded to sample identities for analyses. 
Comparisons between two groups at single time points were analyzed by Student’s t test, or by 
the Mann-Whitney test for measures not satisfying normality assumptions, and comparisons 
between >2 groups employed One-way ANOVA. All statistical tests were calculated using 
GraphPad Prism. Analyses represent mean  SEM of n=5, unless otherwise indicated, and * 
p<0.05, ** p<0.01, *** p<0.001, ****, p<0.0001. The association of hormone level with body 
mass index (BMI) in patients was completed using a linear mixed model incorporating hetero-
skedastic variances aligned with BMI category. A global test of mean differences across BMI 
levels was calculated, and differences in least squares means were used to assess differences 
for BMI groups in relation to lean individuals.  
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Results 
There is an inverse relationship between guanylin mRNA expression in normal colonic 
epithelium and body mass index (BMI) in humans (p<0.001), and morbidly obese patients 
(BMI≥35 kg/m2) exhibit an 80% decrease in guanylin mRNA expression compared to lean 
individuals (Fig. 1A). Loss of guanylin mRNA expression in obesity recapitulated guanylin loss in 
colon tumors compared to matched normal adjacent tissues in patients (12). Similarly, a high 
fat (HF) diet reduced guanylin mRNA expression in normal colon epithelia in mice (Fig. 1B), 
associated with reduced guanylin protein expression (Figs. 1C-D), in proximal and distal colon 
(Supplemental Fig. 1), recapitulating guanylin protein loss in colon tumors in patients (12). Loss 
of guanylin expression in obesity silenced GUCY2C, without changing its expression 
(Supplemental Fig. 2), eliminating canonical cyclic GMP-dependent phosphorylation of the 
vasodilator-stimulated phosphoprotein (VASP) at serine 239 and increasing the expression of β-
catenin (Fig. 1C). Beyond β-catenin, silencing GUCY2C produced characteristic intestinal 
epithelial dysfunction (6, 7, 13) increasing DNA damage (γ-H2AX); activating drivers of 
proliferation (AKT phosphorylation); accelerating the cell cycle (cyclin D1) increasing the 
proliferating crypt compartment (Ki67); and reprogramming metabolism by increasing the 
glycolytic machinery (hexokinase (HK) II; Figs. 1E-F). Epithelial dysfunction produced by guanylin 
suppression and functional silencing of GUCY2C in obesity recapitulated that induced by genetic 
elimination of GUCY2C expression (Fig. 1F). Moreover, in an established model of colon cancer 
in obesity (14), tumorigenesis induced by a HF diet associated with guanylin suppression 
mimicked that produced by genetic silencing of GUCY2C expression (Fig. 1G-H). 
The established paradigm suggests that tumorigenesis associated with diet-induced obesity 
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reflects reprogramming of the endocrine, adipokine, and inflammatory milieu (14-16). 
However, a high carbohydrate (HC) diet which increased caloric intake ~40% (Supplemental Fig. 
1A) without producing weight gain (Supplemental Fig. 1B) reduced colon expression of guanylin 
(Fig. 2A-B), induced epithelial dysfunction (Fig. 2B), and amplified tumorigenesis (Fig. 2C) that 
recapitulated the effects of a HF diet. Also, there is a phenotypic polymorphism in C57BL/6 
mice in which about 20% consume excess calories (Supplemental Fig. 2A) but resist diet-
induced obesity (Supplemental Fig. 2B)(17). These mice, which remain lean on a HF diet, 
nevertheless lose guanylin mRNA (Supplemental Fig. 2C) and protein expression associated with 
epithelial dysfunction marked by increased β-catenin that recapitulates those effects produced 
in obese mice (Fig. 2D). Similarly, while Balb/c mice are genetically resistant to obesogenic diets 
and remain lean (Supplemental Fig. 3A-B)(18), they lose guanylin expression on a HF diet 
(Supplemental Fig. 3C). Further, ob/ob mice have a genetic defect in leptin expression 
producing obesity even on a calorie-restricted Lean diet (Supplemental Fig. 4A-B)(19). However, 
even in the context of obesity (Supplemental Fig. 4b) consumption of a diet restricted to normal 
caloric intake did not reduce guanylin expression or increase β-catenin in ob/ob mice 
(Supplemental Fig. 4C; Fig. 2E). Finally, obese wild type mice on a HF diet recover colonic 
guanylin expression, signaling, and β-catenin levels after 4 wks on a Lean diet (Fig. 2F), although 
they remain persistently obese (Supplemental Fig. 5). Taken together, these observations 
demonstrate that guanylin suppression, GUCY2C silencing and epithelial dysfunction underlying 
intestinal tumorigenesis reflect the quantity of ingested calories, rather than the type of 
calories, or the endocrine, adipokine, and inflammatory milieu associated with obesity. 
Ingesting excess calories induces endoplasmic reticulum (ER) stress associated with an unfolded 
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protein response in extra-intestinal tissues (20, 21). Here, HF or HC diets induced colon ER 
stress in mice, increasing canonical mRNA and protein markers of the unfolded protein 
response (Fig. 3A-B)(21, 22). In that context, ER stress pharmacologically induced by 
tunicamycin or thapsigargin eliminated guanylin expression in Caco2 human colon cancer cells 
in vitro (Fig. 3C-D). Similarly, intraperitoneal (IP) tunicamycin induced ER stress associated with 
loss of guanylin expression in mouse colon (Fig. 3E-F). Further, ER stress genetically induced by 
eliminating expression of Xbp1 (10, 11), a key transcription factor mediating the unfolded 
protein response (21, 22), almost completely abolished colon guanylin expression (Fig. 3G-H). 
Conversely, blocking ER stress in mice on a HF diet by oral supplementation with the chemical 
chaperone taurodeoxycholic acid (TUDCA)(23) reconstituted colonic guanylin expression (Fig. 
3I-J). Similarly, blocking the unfolded protein response by pharmacologic (Fig. 3K) or genetic 
(Fig. 3L) inhibition of PERK, an essential sensor of ER stress (22), restored guanylin expression 
suppressed by tunicamycin in vitro. These observations highlight the role of ER stress and the 
associated unfolded protein response induced by ingested calories as one mechanism 
suppressing the expression of guanylin in obesity. 
The present observations suggest that colon tumorigenesis associated with obesity reflects 
suppression of guanylin expression which silences the GUCY2C tumor suppressor by reversible 
calorie-dependent induction of ER stress and the unfolded protein response in colon epithelial 
cells. This hypothesis was directly tested employing a genetic mouse model in which enforced 
guanylin expression is induced selectively in intestinal epithelial cells (Fig. 4A)(7). Induction of 
transgenic guanylin expression overcame endogenous guanylin suppression and GUCY2C 
silencing, reconstituting VASP phosphorylation and normalizing β-catenin levels in mice on a HF 
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diet (Fig. 4B). Importantly, preventing the loss of guanylin expression and maintaining GUCY2C 
signaling (Fig. 4C) almost completely eliminated intestinal tumorigenesis associated with 
obesity induced by a HF diet (Fig. 4D). 
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Discussion 
While essential molecular details linking energy balance and cancer in any tissue have remained 
elusive, the present study establishes a direct link between signaling pathways underlying colon 
tumorigenesis and mechanisms directly contributing to obesity. In that context, GUCY2C is a 
tumor suppressing receptor whose silencing through loss of the paracrine hormone guanylin 
universally contributes to epithelial dysfunction underlying the initiation of sporadic colorectal 
cancer (1, 2, 4, 6-8, 12, 13). Although loss of guanylin mRNA and protein uniformly characterizes 
the earliest stages of intestinal tumorigenesis (2, 4, 12), the precise molecular mechanisms 
modulating hormone expression remain undefined (1). Here, we reveal that one mechanism 
contributing to guanylin suppression is the induction of ER stress and the unfolded protein 
response (20-22). While a role for ER stress in intestinal tumorigenesis has been suggested (24), 
its role in regulating guanylyl cyclase signaling within, or outside, the intestine has not been 
recognized previously. The prevailing paradigm suggests that intestinal tumorigenesis related to 
obesity reflects dysregulation of the endocrine, adipokine, and inflammatory milieu 
characterizing the associated abnormal metabolic state (14-16). Surprisingly, the present study 
reveals that hormone suppression reflects ER stress induced by hyperphagia and excess 
ingested calories (20, 21), rather than the abnormal metabolic state produced by obesity. 
Indeed, ER stress and hormone suppression was induced by hypercaloric nutrition in the 
absence of obesity in mice on a high carbohydrate diet, and in obesity-resistant Balb/c (17) and 
C57BL/6 (18) mice. Conversely, caloric restriction even in the context of obesity, reconstituted 
guanylin expression in ob/ob (19) and C57BL/6 mice. These studies expand the established 
mechanistic model, adding calorie-induced ER stress to the constellation of processes 
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contributing to tumorigenesis in obesity. 
Mechanistic insights provided here offer unique therapeutic opportunities with immediate 
potential for clinical translation. Indeed, as highlighted in this study, caloric suppression of 
guanylin was reversible, even in the context of persistent obesity. Additionally, conditional 
expression of guanylin by intestinal epithelial cells that could not be suppressed by hyperphagia 
and ingestion of excess calories almost completely eliminated obesity-related colorectal cancer 
in mice. The challenges of lifestyle modification notwithstanding, these observations suggest 
that dietary modification in the form of caloric restriction to reconstitute guanylin expression 
and GUCY2C signaling may be an effective strategy to prevent colon cancer in obesity. Further, 
although guanylin is suppressed in obesity, the GUCY2C tumor suppressor is persistently 
expressed in apical membranes of intestinal epithelial cells, directly accessible to the lumenal 
compartment. These considerations suggest that colon cancer in obesity could be prevented by 
oral ligand supplementation, to replace hormone eliminated by calories and ER stress and 
maintain the GUCY2C tumor suppressor signaling axis. It is noteworthy that linaclotide, an oral 
GUCY2C ligand, received FDA approval for the treatment of constipation-type irritable bowel 
syndrome (25). Moreover, linaclotide recently entered clinical development through the NCI 
Division of Chemoprevention for the oral prophylaxis of colon cancer (ClinicalTrials.gov 
Identifier: NCT01950403). Beyond the colorectum, there is an established epidemiological 
association between obesity and cancer in many tissues (26). In that context, recent studies 
revealed an essential role for the GUCY2C signaling axis in maintaining the intestinal epithelial 
barrier, preventing systemic genotoxic insult associated with extra-intestinal tumorigenesis (9). 
It is tempting to speculate that caloric suppression of guanylin expression, silencing GUCY2C, 
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disrupts the intestinal epithelial barrier, producing systemic genotoxic stress contributing to 
extra-intestinal tumorigenesis in obesity which also could be prevented by oral hormone 
supplementation. 
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Figure Legends 
Figure 1. Suppression of the guanylin-GUCY2C axis with epithelial dysfunction and 
tumorigenesis in obesity in C57BL/6 mice. (A) Guanylin mRNA in human colon inversely 
correlates with BMI. (B) Guanylin mRNA in colons from mice on high fat (HF) or Lean diets. (C) 
Loss of guanylin in mice on HF diet silences GUCY2C, increasing epithelial dysfunction. (D) 
Guanylin (green), β-catenin (red) and (E) Ki67 in colons from mice on Lean and HF diets. (F) 
Epithelial dysfunction was compared in GUCY2C wild type (+/+) and deficient (-/-) mice on Lean 
and HF diets. (G) Tumor number and (H) burden in GUCY2C (+/+) and (-/-) mice on Lean or HF 
diet receiving AOM. Immunoblot results represent the mean + SEM of 5 mice. 
Figure 2. Guanylin expression is reversibly suppressed by ingested calories. (A) High 
carbohydrate (HC) and HF diets suppressed guanylin mRNA in colon. (B) HC diet reduced 
guanylin and GUCY2C signaling, increasing epithelial dysfunction. (C) Mice fed a HC, compared 
to a Lean, diet are more sensitive to AOM-induced colon tumorigenesis. (D) HF diet reduced 
guanylin and GUCY2C signaling, increasing epithelial dysfunction, in mice resistant to diet-
induced obesity (HF-R). (E) ob/ob on a calorie-restricted diet (10 Kcal/d per mouse) maintained 
guanylin expression and GUCY2C signaling, without epithelial dysfunction. (F) Diet effects on 
guanylin expression, GUCY2C signaling, and epithelial dysfunction were reversed by switching 
mice on a HF diet for 20 wks to a Lean diet for 4 wks (HF-Lean). Immunoblot results represent 
the mean + SEM of 5 mice. 
Figure 3. ER stress mediates guanylin suppression by ingested calories. (A) High calorie diets 
induced the transcription (A) and translation (B) of markers of ER stress in colon in C57BL/6 
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mice. (C-D) ER stress induced by 2.5 g/ml tunicamycin (TM) or 500 nM thapsigargin (TSG) 
increased markers of ER stress and suppressed guanylin in Caco2 cells. (E-F) IP administration of 
1 mg/kg TM to C57BL/6 mice increased markers of ER stress and suppressed guanylin 
expression in colon. (G-H) Colons from Xbp1ΔIEC mice exhibited reduced expression of guanylin 
(green) compared to wild type (Xpbfl/fl) mice [β-catenin (red)]. (I-J) TUDCA (150 mg/kg by oral 
gavage for 12 d) relieved ER stress and rescued guanylin expression in C57BL/6 mice on a HF 
diet. (K) Inhibition of PERK by GSK2606414 relieved ER stress and restored guanylin expression 
in Caco2 cells treated with TM. (L) PERK siRNA restored guanylin expression in HEK 293 cells 
treated with 1.0 g/ml TM. In vitro results represent the mean + SEM of three independent 
experiments performed in triplicate. In vivo results represent the mean + SEM of 5 mice unless 
otherwise indicated. 
Figure 4. Transgenic guanylin expression prevents calorie-induced tumorigenesis. (A) 
Construct for transgenic guanylin expression in intestine. Transgenic guanylin expression (B) 
rescued GUCY2C signaling reducing epithelial dysfunction induced by a HF diet and (C-D) almost 
completely eliminated tumorigenesis induced by a HF diet and AOM in colons of VilGuca2a+, 
but not control VilGuca2a-, mice. Immunoblot results represent the mean + SEM of 5 mice. 
VilGuca2a (-), C57BL/6 mice expressing vil-Cre-ERT2 (guanylin wild type); VilGuca2a (+), C57BL/6 
mice expressing vil-Cre-ERT2 and carrying the guanylin transgene. 
